the aid library

Filter

750

Regional Guidelines for the Management of Severe Falciparum Malaria in Large Hospitals

World Health Organization (WHO), Regional Office for South-East Asia (2006) C_WHO

hese are two parallel guidelines, one for small hospitals and another one for large hospitals. In view of heavy burden of malaria and prevalence of drug resistant falciparum malaria in the South-East Asia Region, the guidelines were developed for us ... more

A Field Guide to Antibiotic Stewardship in Outpatient Settings

Telligen, Quality Innovation Network National Coordinating Center, Centers for Medicare & Medicaid Services (CMS) (2018) C2

Antibiotic Stewardship (AS) is a coordinated program that promotes the appropriate use of antimicrobials to improve patient outcomes, reduce microbial resistance, and decrease the spread of multi-drug resistant organisms. In clinical settings, stewa ... more

Tackling Antimicrobial Resistance (AMR) Together Working Paper 1.0: Multisectoral coordination

World Health Organization WHO (2018) C_WHO

This working paper was conceived to offer practical tips and suggestions on how to establish and sustain the multisectoral coordination needed to develop and implement National Action Plans on AMR (NAPs). It is intended for anyone with responsibility for addressing AMR at country level. Drawing on b ... more

WHO consolidated guidelines on tuberculosis - Module 5: Management of tuberculosis in children and adolescents
recommended

World Health Organization WHO (2022) C_WHO

The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Security Survey for Health Facilities
recommended

International Committee of the Red Cross (ICRC) (2017) C1

The purpose of the survey is to identify the level of preparedness required by a health-care facility to be able to continue operating during, or following a conflict-related security event.
The survey method provides a measure of the security and preparedness of a given health facility in it ... more

Planetary health and the role of community health workers

Manas R. , Behera R., Satpathy S.K. J Family Med Prim Care (2020) C1

In this era, grand challenges lies in biodiversity loss, climate change, and global noncommunicable diseases signify that planet and humanity are in crisis. Scholarly evidence from human and animal kingdom suggest that there is an optimism in planetary health which can provide a unique and novel con ... more

MENTAL HEALTH AND INTEGRATION: PROVISION FOR SUPPORTING PEOPLE WITH MENTAL ILLNESS: A COMPARISON OF 15 ASIA-PACIFIC COUNTRIES

The Economist Intelligence Unit Limited Jannsen (2016) C1

An Economist Intelligence Unit briefing paper | The Economist Intelligence Unit (EIU) undertook a study aimed at assessing the degree of commitment of 15 countries within the AsiaPacific region to integrating those with mental illness into their communities. The research was commissioned and funded ... more

Guide Material for Medical Store Management Training
recommended

Community Development Medicinal Unit (2012) C_WHO

Drugs and medical supplies are dispensed at the cutting edge level of the interface between the public health system and the people. Availability or lack of it brings either credit or discredit to the public health system. The primary reason for holding stocks of medicines and medical supplies in a ... more

Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update

Lalloo, U.G.; Kalla, I.S.; Abdool-Gaffar, S. et al. African Journal of Thoracic and Critical Care Medicine (2021) CC

sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ... more

Fever Diagnostic Technology Landscape
recommended

UNITAID World Health Organisation (WHO) (2018) C_WHO

1st edition. Unitaid’s report describes a slate of new devices that can more efficiently identify dangerously ill children so that they can be treated immediately. These tools make it easier to recognize danger signs, and support integrated approaches to reducing childhood deaths from the three ... more

MSF Essential Drugs - Practical Guidelines 2022
recommended

Médecins sans Frontières MSF Médecins sans Frontières (2022) C2

Practical guide intended for physicians, pharmacists, nurses and medical auxiliaries. This guide is not a dictionary of pharmacological agents. It is a practical manual intended for health professionals, physicians, pharmacists, nurses and health auxiliaries invoved in curative care and ... more

Contextual factors influencing schistosomiasis treatment and identification of delivery platforms for arpraziquantel in hard-to-reach areas and populations in Homa Bay County, Kenya

Isaiah PM, Afriyie DO, Maghanga M, (2024) CC

PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035. A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool- aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and elimination program ... more

Health Pictograms

Rhodes University (2022) CC

Our target end-users are those with limited literacy. It is a challenging task to achieve success in this group as so much of what is "obvious" to those of us with good literacy skills is totally obscure to those who have never had the opportunity to learn the meaning of e.g. an arrow shape and what ... more

GOOD MANUFACTURING PRACTICE GUIDELINES FOR PHARMACEUTICAL PRODUCTS

National Agency for Food and Drugs Administration and Control (NAFDAC), Nigeria (2016) C2

WHO Guidelines on Good Manufacturing Practices (GMP) for Herbal Medicine
recommended

World Health Organization WHO (2007) C_WHO

The manufacturing process is one of the key steps where quality control is required to ensure quality of medicinal products, including herbal medicines. Good manufacturing practices (GMP) is one of the most important tools for this measure.

World Health Organization model list of essential medicines for children: 10th list
recommended

World Health Organization WHO (2025) C_WHO

The WHO Model List of Essential Medicines and Model List of Essential Medicines for Children are updated and published every two years, intended as a guide for countries or regional authorities to adopt or adapt in accordance with local priorities and treatment guidelines for the development and upd ... more

HIV and young people who inject drugs

A. Armstrong; J. Baer; R. Baggaley; et al. UNAIDS; World Health Organization; UNFPA; et al. (2015) C_WHO

Technical Brief

Glossary of terms used in Pharmacovigilance

World Health Organization (WHO) (2011) C_WHO

Nepal: Drugs Act, 2035, (1978)

World Health Organisation (WHO) (2000) C_WHO